Skip to main content

Advertisement

SpringerLink
Log in

Next-generation antibodies

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This article has been updated

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Market potential for NGA products, 2013–2021.

Change history

  • 29 April 2014

    There was a small error in the Figure 1 title (it should refer to the 2013–2021 period, not 2012–2020). This has now been updated online.

References

  1. Reichert, J. M. Which are the antibodies to watch in 2013? MAbs 5, 1–4 (2013).

    Article  Google Scholar 

  2. Visiongain. Next-Generation Antibody Therapeutics Market 2013–2023 (Visiongain, 2013).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Visiongain, BSG HOUSE, 230 City Road, London, EC1V 2QY, UK

    James B. Evans

  2. IMS Health, 210 Pentonville Road, London, N1 9JY, UK

    Basharut A. Syed

Authors
  1. James B. Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Basharut A. Syed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Basharut A. Syed.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Evans, J., Syed, B. Next-generation antibodies. Nat Rev Drug Discov 13, 413–414 (2014). https://doi.org/10.1038/nrd4255

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4255

  • Springer Nature Limited

This article is cited by

Search

Navigation